English | Español

Novartis
Amanda Rupp | Aug 31, 2016

Sandoz's Erelzi gains FDA approval for multiple inflammatory diseases
Jamie Barrand | Feb 20, 2016

Novartis' new AML therapy granted FDA Breakthrough Designation
Jamie Barrand | Feb 20, 2016

Alcon, Transcend Medical partner on glaucoma therapy project
Jamie Barrand | Feb 13, 2016

Sandoz acquires infliximab inhibitor treatment from Pfizer
Kasey Schefflin- Emrich | Jan 28, 2016

FDA approves Cosentyx as treatment for two inflammatory conditions

Trending
+ Technology/Innovation
Patient Daily | May 8, 2025

Medfluence attends 2025 Annual Clinical Assembly as only strategic marketing firm
+ Technology/Innovation
Patient Daily | May 7, 2025

OTO Forum 2025 highlights innovation in ENT
+ Pharmaceuticals
Patient Daily | May 8, 2025

Pacific Research Institute CEO: Hospitals are leveraging 340B's 'perverse incentives to enrich themselves'
+ Pharmaceuticals
Patient Daily | May 8, 2025

National Library of Medicine says compounded drugs like GLP-1 offer tailored alternatives to FDA-approved treatments